Why is Moderna stock rallying today?

The FDA approved 13 drugs in August 2026, including Moderna's mFLUSIVA ($149.56/dose) for influenza prevention, Takeda's Orezyful for narcolepsy, Replimune's Tudriqev ($450,000/course) for melanoma, Bristol-Myers Squibb's Zenbexus ($29,500/28-day cycle) for multiple myeloma, Lantheus' Tauklarify for Alzheimer's diagnosis, and Regeneron's Pasatru for FOP. Each drug showed positive clinical trial results.

The FDA approved Moderna's mFLUSIVA, the first mRNA flu vaccine for adults 50+ in the U.S. It showed 26.6% higher efficacy than standard flu vaccines in trials. Availability is expected during the 2026-2027 flu season, with insurance details pending. The CDC recommends annual flu vaccines for all ages 6 months and older.

Moderna Inc. doubled the list price of its RSV vaccine, mRESVIA, to around $640 per dose in the U.S., aiming to reflect mRNA technology value and offset development costs. Shares surged, but analysts warn of potential payer pushback. The vaccine's uptake has lagged behind rivals like GSK and Pfizer, with 2023 sales under $25 million. A European Commission contract for up to 24 million doses offers a lifeline. Moderna targets 10% growth in 2026, with RSV and other respiratory vaccines as key cont

Moderna (MRNA) and Merck (MRK) announced positive Phase 3 trial results for their personalized mRNA cancer vaccine, Intismeran Autogene, combined with Keytruda. The treatment extended survival without melanoma recurrence. MRNA stock surged 177%, MRK rose 12%. The vaccine's personalized nature and high cost may pose insurance coverage challenges. FDA approval is expected in 2027-2028. The treatment is not yet commercially priced, with estimates exceeding $150,000 per patient.

Target reported Q2 earnings with a 5.3% sales increase and 3.8% same-store sales growth, driven by a $994M tariff refund and 20% fundamental EPS growth. The company is focusing on digital sales and price cuts to attract budget-conscious shoppers. Moderna's stock surged 135% following positive Phase 3 trial results for its mRNA-based personalized cancer vaccine, a significant milestone in cancer treatment.

The FDA approved Moderna's mRNA flu vaccine, citing 26.6% higher efficacy than traditional vaccines. However, an analysis of trial data revealed a statistically significant increase in serious adverse events (SAEs) in the mRNA group. The FDA used pooled data from multiple trials to dilute this safety signal, despite acknowledging potential variations. Concerns also arise from higher mortality rates in mRNA groups across trials.